Lohmann Rauscher (LR): Personnel Change in Executive Board of LR

Food and Healthcare Press Releases Friday January 26, 2018 09:15
VIENNA and RENGSDORF, Germany--26 Jan--PRNewswire/InfoQuest

In January 2018, a change in the Executive Board of manufacturer and supplier of medical devices, Lohmann & Rauscher (L&R), took place after the former Chief Commercial Officer, Markus Sebastian, had resigned.

The Advisory Board and the CCO mutually agreed that Markus Sebastian is going to leave the Lohmann & Rauscher Corporate Group by the end of January 2018 to pursue new tasks and face new challenges.
Responsibility for the business unit Marketing & Sales will be assumed by Dipl.-Ing. Wolfgang Suessle, President & CEO, on a transitional basis.
Reprint free of charge - specimen copy requested
Lohmann & Rauscher Corporate Group

Lohmann & Rauscher (L&R) is a leading international supplier of high-quality medical devices and hygiene products ranging from conventional dressing material to modern treatment and nursing systems. Created in 1998 through the merger of Lohmann (founded in 1851) and Rauscher (founded in 1899), L&R has more than 160 years' expertise as a reliable solution provider for its customers.

With 4,600 employees, 44 corporate subsidiaries and shareholdings and more than 130 select partners, the company is active in all of the world's key markets. The L&R Group was able to realize a sales of EUR604,2 million in 2017. The L&R headquarters are located in Rengsdorf (Germany) and Vienna (Austria).

L&R's entrepreneurial spirit is reflected in the Group's claim of People.Health.Care.: the human, the health, and the care for both.
Further information on Lohmann & Rauscher (L&R) can be found at:
http://www.lohmann-rauscher.com
Press Contact:
Lohmann & Rauscher International GmbH & Co. KG
Public Relations
Sabrina Klein
Johann-Schorsch-Gasse 4 1140 Vienna
Tel.: +43-1-57670-386 Fax DW: 9386
E-Mail: Sabrina.Klein@at.LRmed.com
http://www.lohmann-rauscher.com
Source: Lohmann & Rauscher

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics